Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agios Pharmaceuticals excels in Q4, eyes hematology franchise expansion

Agios Pharmaceuticals showcased strong performance and progress in its Q4 2022 earnings call, emphasizing advancements in its pipeline and commercial capabilities. While facing challenges in estimating sales and patient enrollment progression, the company is well-positioned to capitalize on opportunities for growth and expansion.

Agios Pharmaceuticals reports robust Q1 earnings and strategic growth outlook

Agios Pharmaceuticals demonstrated strong financial performance, progress in PK activation therapies, and strategic decision-making in Q1 2023.
While facing challenges in distribution and inventory management, the company's focus on persistency, clear milestones, and launch dynamics present growth opportunities.
Overall, Agios Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges, and leverage opportunities for future success.

Agios Pharmaceuticals reports strong Q2 performance and eyes growth opportunities

Agios Pharmaceuticals shows strong financial performance and pipeline progress.
Challenges include slow uptake for PYRUKYND and clinical development queries.
Exciting opportunities lie in potential acquisitions, peak sales targets, and upcoming data readouts.

Agios Pharmaceuticals excels in Q3, poised for growth and innovation

Agios Pharmaceuticals delivered a strong performance in Q3 2023, achieving key milestones and reporting solid financial results, positioning the company for future growth.
With a focus on pipeline advancements, commercial success, and financial stability, Agios demonstrates resilience and potential in the competitive pharmaceutical landscape.
While facing challenges in competitive markets and the need for further clarity on certain aspects, Agios has opportunities to capitalize on its strengths and drive innovation and growth.

Agios Pharmaceuticals reports robust earnings and eyes market expansion

Agios Pharmaceuticals showcased strong performance in PK activator development, with positive data readouts and financial stability driving growth prospects.
While facing challenges in market differentiation and regulatory approval, the company's strategic strengths in rare disease treatments and operational efficiency position it for long-term success.
With upcoming launches for thalassemia and sickle cell disease, Agios has opportunities to expand its market presence, drive revenue growth, and establish itself as a key player in rare disease therapeutics.

Agios Pharmaceuticals excels in Q1, eyes strong growth opportunities

Agios Pharmaceuticals showcased strong performance with positive clinical data and solid financials.
While facing challenges in market dynamics and cost management, the company is optimistic about future opportunities.
With a focus on partnerships and revenue growth, Agios aims to deliver value to shareholders.
The company's robust pipeline and cash position position it well for future success.

Agios Pharmaceuticals reports robust Q3 performance and eyes future launches

Agios Pharmaceuticals showcased strong financial performance and progress in key therapeutic areas during their Q3 2024 earnings call. While facing challenges in addressing analyst inquiries and market comparisons, the company remains optimistic about their future prospects. Leveraging their strengths in market engagement and scientific innovation, Agios is well-positioned for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the appointments of Rahul Ballal, Ph.D., chief executive officer of Imara, and Cynthia Smith, former chief commercial officer of ZS Pharma, to its board of directors.

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND ® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 –

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the grant of inducement equity awards outside of the company's 2013 Stock Incentive Plan to its newly appointed chief executive officer, Brian Goff. The grants were approved by the board of directors effective as of August 8, 2022 as inducements material to Mr. Goff entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Holly Manning - Senior Director, Investor Relations Jackie Fouse - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head of R&D Richa Poddar - Chief Commercial Officer Jonathan Biller - Chief Financial Officer and Head of Corporate Affairs Conference Call Participants Marc Frahm - Cowen Andrew Berens - SVB Leerink Danielle Brill - Raymond James Operator Good morning and welcome to Agios Second Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q2 2022 Results - Earnings Call Transcript

Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat

– Generated $3.1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND ® (mitapivat) Sales –

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

Agios sold its first successful commercial drug to Servier for $2 billion. Launch of second drug, Pyrukynd, is underway.

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, August 4, 2022, at 8:00 a.m. ET to report its second quarter 2022 financial results and other business highlights.

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

– Current CEO, Jackie Fouse, Ph.D., to Transition to Chair of Board of Directors Effective August 8, 2022 –

Agios Appoints Brian Goff as Chief Executive Officer

– Treatment with PYRUKYND ® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at Least Once –

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July –

Agios Announces Evolution of Research Organization

– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND ® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions –

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

Mitapivat got approved for PK deficiency. They have multiple label expansion potential.

Agios: Approved Product, Upcoming Catalysts

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 10:30 a.m. ET.

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Jackie Fouse – Chief Executive Officer Sarah Gheuens – Chief Medical Officer Richa Poddar – Chief Commercial Officer Jonathan Biller – Chief Financial Officer and Head of Corporate Affairs Holly Manning – Senior Director of Investor Relations Conference Call Participants Anupam Rama – J.P. Morgan Marc Frahm – Cowen and Company Greg Harrison – Bank of America Mark Breidenbach – Oppenheimer Matt Carter – Goldman Sachs Andrew Berens – SVB Securities Danielle Brill – Raymond James Operator Ladies and gentlemen, please stand by your conference call will begin momentarily.

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q1 2022 Results - Earnings Call Transcript

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates

– Received U.S. FDA Approval for PYRUKYND ® , the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios' First Genetically Defined Disease Medicine; U.S. Launch Underway –

Agios Reports Business Highlights and First Quarter 2022 Financial Results

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, May 5, 2022, at 8:00 a.m. ET to report its first quarter 2022 financial results and other business highlights.

Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND ® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes –

Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q4 2021 Results - Earnings Call Transcript

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates

– Received FDA Approval of PYRUKYND ® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder –

Agios Reports Fourth Quarter and Full Year 2021 Financial Results

Pyrukynd (mitapivat) was approved by the FDA on February 17. Agios is cash rich from the sale of its cancer drug division.

Agios Pharmaceuticals With FDA Approval Is A Buy

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

News for Agios Pharmaceuticals Stock (AGIO)